SM04690の新興薬剤に関する洞察と市場予測：2032年

Lorecivint（SM04690）はWnt経路の低分子阻害剤で、関節内注射剤として投与され、変形性関節症の疾患修飾薬（DMOAD）として開発中です。媒剤対照前臨床試験データから、lorecivivintは、軟骨の生成、軟骨の破壊の遅延、炎症の抑制という、関節の健康に対する3つの効果を持つ二重の作用機序を持つことが示唆されています。核内キナーゼであるCLK2とDYRK1Aを阻害することで、Wnt経路、軟骨細胞、炎症に作用します。LORのこの二重のメカニズムは、軟骨細胞の分化と機能の増加を通じてOAを改善し、抗炎症活性を通じて症状を改善する可能性があります。

当レポートでは、主要6ヶ国、カナダおよび韓国におけるSM04690市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 変形性関節症に対するSM04690の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 SM04690市場評価

• 変形性関節症に対するSM04690の市場展望
• 主要6ヶ国、カナダおよび韓国の分析
  • 主要6ヶ国、カナダおよび韓国における変形性関節症に対するSM04690の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • カナダ
  • 韓国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: SM04690, Clinical Trial Description, 2023
• Table 2: SM04690, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: SM04690 Market Size in the 6MM, Canada and Korea, in USD million (2019-2032)
• Table 6: SM04690 Market Size in the US, in USD million (2019-2032)
• Table 7: SM04690 Market Size in Germany, in USD million (2019-2032)
• Table 8: SM04690 Market Size in France, in USD million (2019-2032)
• Table 9: SM04690 Market Size in Italy, in USD million (2019-2032)
• Table 10: SM04690 Market Size in Spain, in USD million (2019-2032)
• Table 11: SM04690 Market Size in the UK, in USD million (2019-2032)
• Table 12: SM04690 Market Size in Canada, in USD million (2019-2032)
• Table 13: SM04690 Market Size in Korea, in USD million (2019-2032)

List of Figures

• Figure 1: SM04690 Market Size in the 6MM, Canada and Korea, USD million (2019-2032)
• Figure 2: SM04690 Market Size in the United States, USD million (2019-2032)
• Figure 3: SM04690 Market Size in Germany, USD million (2019-2032)
• Figure 4: SM04690 Market Size in France, USD million (2019-2032)
• Figure 5: SM04690 Market Size in Italy, USD million (2019-2032)
• Figure 6: SM04690 Market Size in Spain, USD million (2019-2032)
• Figure 7: SM04690 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: SM04690 Market Size in Canada, USD million (2019-2032)
• Figure 9: SM04690 Market Size in Korea, USD million (2019-2032)

“"SM04690 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SM04690 for osteoarthritis in the six major markets. A detailed picture of the SM04690 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SM04690 for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SM04690 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

Lorecivivint (SM04690) is a small-molecule inhibitor of the Wnt pathway administered as an intra-articular injection and is developing as a potential disease-modifying drug for osteoarthritis (DMOAD). Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three effects on joint health: generation of cartilage, slowing of cartilage breakdown, and reduction of inflammation. Inhibition of nuclear kinases CLK2 and DYRK1A leads to effects on the Wnt pathway, chondrocytes, and inflammation. This dual mechanism of LOR potentially modifies OA through increased chondrocyte differentiation and function and benefits symptoms through anti-inflammatory activity.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SM04690 description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on SM04690 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SM04690 research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around SM04690.
• The report contains forecasted sales of SM04690 for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for SM04690 in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SM04690 Analytical Perspective by DelveInsight

• In-depth SM04690 Market Assessment

This report provides a detailed market assessment of SM04690 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

• SM04690 Clinical Assessment

The report provides the clinical trials information of SM04690 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SM04690 dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to SM04690 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SM04690 in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of SM04690 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SM04690 in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of SM04690?
• What is the clinical trial status of the study related to SM04690 in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SM04690 development?
• What are the key designations that have been granted to SM04690 for osteoarthritis?
• What is the forecasted market scenario of SM04690 for osteoarthritis?
• What are the forecasted sales of SM04690 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to SM04690 for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. SM04690 Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SM04690 Market Assessment

• 5.1. Market Outlook of SM04690 in Osteoarthritis
• 5.2. 6MM, Canada and Korea Analysis
  • 5.2.1. Market Size of SM04690 in the 6MM, Canada and Korea for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SM04690 in the United States for Osteoarthritis
  • 5.3.2. Market Size of SM04690 in Germany for Osteoarthritis
  • 5.3.3. Market Size of SM04690 in France for Osteoarthritis
  • 5.3.4. Market Size of SM04690 in Italy for Osteoarthritis
  • 5.3.5. Market Size of SM04690 in Spain for Osteoarthritis
  • 5.3.6. Market Size of SM04690 in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of SM04690 in Canada for Osteoarthritis
  • 5.3.8. Market Size of SM04690 in Korea for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options